Exhibit 10.1  
 CONSULTING AGREEMENT  
 THIS CONSULTING AGREEMENT (“Agreement”) dated November 18, 2020, is by and between Aditx Therapeutics, Inc. (Nasdaq: ADTX) with its principal place of business located at 0000 Xxxxxxxxx Xx. Xxxxx 000, Xxxxxxxx Xxxx, XX 00000 (“Aditxt”) and Salveo Diagnostics, Inc., with its principal place of business located at 0000 Xxxx Xxxxxxx Xxxxx, #000, Xxxxxxxx, Xxxxxxxx 00000 (“Salveo”) (each referred to individually as a “Party” and together, referred to as the “Parties”).  
 WHEREAS, Aditxt is a life sciences company with an interest in immune monitoring using an advanced diagnostic platform (“AditxtScore™”) to rapidly profile the immune system to anticipate responses and possible reactions to viruses, bacteria, allergens and transplanted organs;  
 WHEREAS, Salveo is a duly licensed and fully accredited independent clinical and diagnostics laboratory that is accredited by the College of American Pathologists (“CAP”) and certified by the Clinical Laboratory Improvement Amendments (“CLIA”);  
 WHEREAS, Aditxt desires to establish, setup and commence commercial operations of its own licensed, CAP accredited, and CLIA certified independent clinical and diagnostic laboratory (the “AditxtScore™ Center”) in the Richmond, Virginia area;  
 WHEREAS, Aditxt wishes to engage Salveo upon the terms and conditions contained herein; and  
 WHEREAS, Salveo is willing to be engaged by Aditxt upon the terms and conditions contained herein.  
 NOW, THEREFORE, acknowledging the receipt of adequate consideration and intending to be legally bound by the mutual promises, covenants, and conditions herein, the Parties agree as follows:  
 1. Services. Salveo shall provide the following services for Aditxt (the “Services”):